Tests HRS-7535 for high blood pressure in adults with overweight or obesity
Tests HRS-7535 against placebo in adults with high blood pressure and excess weight.
Plain-language title generated from the registry record
Registry title: Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
Key facts
- Where
- Beijing and Harbin, ChinaSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07528027, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
- The First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shandong Suncadia Medicine Co., Ltd.
- Trial code
- NCT07528027
- Record updated
- 24 September 2026
- Original description
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 for the Treatment of Hypertension in Participants With Obesity or Overweight
The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
Inclusion: On the day of signing the informed consent form, the age should be between 18 and 70 years old, with no gender restrictions; When screening and randomizing, the average office blood pressure meets any of the following conditions: ① 140 mmHg ≤ SBP < 170 mmHg, and DBP < 110 mmHg; ② 90 mmHg ≤ DBP < 110 mmHg, and 130 mmHg ≤ SBP < 170 mmHg; Patients with untreated hypertension, or those who have received stable doses of any or all of the following classes of antihypertensive medications within 30 days prior to screening: 1) angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), 2) thiazides and thiazide-like diuretics, 3) calcium channel blockers. Patients who are currently receiving stable doses of beta blockers (such as metoprolol or atenolol) or mineralocorticoid receptor antagonists (such as spironolactone) and intend to continue these treatments at their current doses may be included in this study; During screening, BMI should be ≥24 kg/m2.
Exclusion: Those who have undergone coronary revascularization within the previous 90 days or plan to undergo it during the trial period; Having a known secondary cause of hypertension; Diagnosed or suspected with type 1 diabetes, special type of diabetes, or secondary diabetes (excluding gestational diabetes); History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/requiring treatment of gallbladder disease (excluding those who have undergone cholecystectomy but are still eligible for enrollment as determined by the investigator); History of previously diagnosed heart failure with reduced ejection fraction (HFrEF).